Dear ,

In the current issue of the OncoWuXi Newsletter, we share updates on our services and newly established capabilities.
 
The OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of WuXi Biology, our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases. We are your ideal partner for enabling technological breakthroughs and accelerating cancer drug discovery.
Xenograft and Syngeneic Tumor Models in Rats
(1)  26 human cell-line derived xenograft models covering 12 cancer types

(2)  15 rat cell-line derived syngeneic models covering 12 cancer types
Immuno-Oncology
CD47/SIRPĪ±-related in vitro assay platform

(1)  CD47-SIRPĪ± interaction blocking/inhibitory assays
  • Protein based HTRF & AlphaLISA blocking/inhibitory assays
  • Cell based blocking/inhibitory assays

(2)  In vitro effector function
  • FACS & cell based binding assay
  • Phagocytosis assay

(3)  Safety assessments
  • Antibody binding assay on RBCs of NHP
  • Hemolysis assay on RBCs of NHP
Customized Formula Diet Platform
(1)  Formula diet-influenced tumor model solution

(2)  Formula diet-controlled disease model solution
We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
 
Best regards,
WuXi AppTec OncoWuXi Team